Isofol Medical AB (publ) (ISOFOL.ST)
SEK 1.77
(-0.62%)
SEK 1.77
(-0.62%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -37.07 Million SEK | 76.23% |
| 2022 | -155.94 Million SEK | 20.79% |
| 2021 | -196.88 Million SEK | -4.18% |
| 2020 | -188.99 Million SEK | -20.2% |
| 2019 | -157.23 Million SEK | -89.15% |
| 2018 | -83.12 Million SEK | -15.4% |
| 2017 | -72.03 Million SEK | -12.52% |
| 2016 | -64.01 Million SEK | -57.33% |
| 2015 | -40.68 Million SEK | 0.0% |
| 2011 | -10.6 Million SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -11.04 Million SEK | -30.22% |
| 2024 Q1 | -8.48 Million SEK | 4.51% |
| 2023 Q4 | -8.88 Million SEK | -41.9% |
| 2023 FY | -37.07 Million SEK | 76.23% |
| 2023 Q1 | -14.39 Million SEK | 42.63% |
| 2023 Q2 | -7.5 Million SEK | 47.84% |
| 2023 Q3 | -6.26 Million SEK | 16.61% |
| 2022 Q2 | -50.91 Million SEK | -14.33% |
| 2022 FY | -155.94 Million SEK | 20.79% |
| 2022 Q1 | -44.53 Million SEK | 27.2% |
| 2022 Q4 | -25.08 Million SEK | 15.94% |
| 2022 Q3 | -29.84 Million SEK | 41.37% |
| 2021 Q4 | -61.17 Million SEK | -19.88% |
| 2021 FY | -196.88 Million SEK | -4.18% |
| 2021 Q1 | -42.66 Million SEK | 21.95% |
| 2021 Q2 | -45.39 Million SEK | -6.4% |
| 2021 Q3 | -51.02 Million SEK | -12.41% |
| 2020 Q3 | -30.1 Million SEK | 37.71% |
| 2020 Q4 | -54.65 Million SEK | -81.59% |
| 2020 FY | -188.99 Million SEK | -20.2% |
| 2020 Q1 | -55.91 Million SEK | 3.45% |
| 2020 Q2 | -48.31 Million SEK | 13.58% |
| 2019 FY | -157.23 Million SEK | -89.15% |
| 2019 Q4 | -57.91 Million SEK | -38.05% |
| 2019 Q1 | -26.96 Million SEK | 6.97% |
| 2019 Q3 | -41.95 Million SEK | -20.71% |
| 2019 Q2 | -34.75 Million SEK | -28.88% |
| 2018 Q4 | -28.98 Million SEK | -67.54% |
| 2018 FY | -83.12 Million SEK | -15.4% |
| 2018 Q2 | -16.94 Million SEK | 14.77% |
| 2018 Q1 | -19.88 Million SEK | 22.64% |
| 2018 Q3 | -17.3 Million SEK | -2.08% |
| 2017 Q3 | -19.25 Million SEK | -40.4% |
| 2017 FY | -72.03 Million SEK | -12.52% |
| 2017 Q1 | -13.19 Million SEK | 56.8% |
| 2017 Q2 | -13.71 Million SEK | -3.93% |
| 2017 Q4 | -25.7 Million SEK | -33.5% |
| 2016 Q4 | -30.54 Million SEK | -249.19% |
| 2016 Q1 | -14.73 Million SEK | -40.36% |
| 2016 FY | -64.01 Million SEK | -57.33% |
| 2016 Q2 | -10.68 Million SEK | 27.51% |
| 2016 Q3 | -8.74 Million SEK | 18.14% |
| 2015 FY | -40.68 Million SEK | 0.0% |
| 2015 Q4 | -10.5 Million SEK | 0.0% |
| 2011 FY | -10.6 Million SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Alzinova AB (publ) | -16.48 Million SEK | -124.945% |
| Amniotics AB (publ) | -30.87 Million SEK | -20.087% |
| Asarina Pharma AB (publ) | -12.82 Million SEK | -188.985% |
| BioArctic AB (publ) | 229.24 Million SEK | 116.171% |
| Calliditas Therapeutics AB (publ) | -466.18 Million SEK | 92.048% |
| Genovis AB (publ.) | 61.5 Million SEK | 160.278% |
| LIDDS AB (publ) | -40.2 Million SEK | 7.797% |
| Magle Chemoswed Holding AB (publ) | 12.16 Million SEK | 404.635% |
| OncoZenge AB (publ) | -15.9 Million SEK | -133.122% |
| Saniona AB (publ) | -95.81 Million SEK | 61.308% |
| Simris Alg AB (publ) | -37.3 Million SEK | 0.627% |
| Vicore Pharma Holding AB (publ) | -310.94 Million SEK | 88.078% |
| AcouSort AB (publ) | -17.08 Million SEK | -116.929% |
| Active Biotech AB (publ) | -45.8 Million SEK | 19.059% |
| Camurus AB (publ) | 431.44 Million SEK | 108.592% |
| Cantargia AB (publ) | -280.02 Million SEK | 86.762% |
| Scandinavian ChemoTech AB (publ) | -21.09 Million SEK | -75.767% |
| Guard Therapeutics International AB (publ) | -113.32 Million SEK | 67.287% |
| Mendus AB (publ) | -101.61 Million SEK | 63.52% |
| Kancera AB (publ) | -64.88 Million SEK | 42.87% |
| Karolinska Development AB (publ) | 5.38 Million SEK | 788.284% |
| Lipum AB (publ) | -37.17 Million SEK | 0.288% |
| Lipigon Pharmaceuticals AB (publ) | -12.12 Million SEK | -205.665% |
| NextCell Pharma AB | -41.95 Million SEK | 11.651% |
| Xbrane Biopharma AB (publ) | -388.17 Million SEK | 90.45% |
| Xintela AB (publ) | -54.08 Million SEK | 31.455% |
| Ziccum AB (publ) | -21.41 Million SEK | -73.132% |
| Elicera Therapeutics AB (publ) | -16.39 Million SEK | -126.071% |
| Modus Therapeutics Holding AB (publ) | -17.89 Million SEK | -107.135% |
| Xspray Pharma AB (publ) | -179.66 Million SEK | 79.367% |
| CombiGene AB (publ) | -35.66 Million SEK | -3.941% |
| Diamyd Medical AB (publ) | -151.85 Million SEK | 75.587% |
| Intervacc AB (publ) | -102.85 Million SEK | 63.957% |
| Alligator Bioscience AB (publ) | -248.58 Million SEK | 85.087% |
| Sprint Bioscience AB (publ) | -438 Thousand SEK | -8363.699% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -16.52 Million SEK | -124.36% |
| Corline Biomedical AB | -1.8 Million SEK | -1949.254% |
| IRLAB Therapeutics AB (publ) | -177.83 Million SEK | 79.155% |
| Bio-Works Technologies AB (publ) | -56.82 Million SEK | 34.758% |
| Aptahem AB (publ) | -11.11 Million SEK | -233.586% |
| Infant Bacterial Therapeutics AB (publ) | -123.06 Million SEK | 69.878% |
| Fluicell AB (publ) | -26.55 Million SEK | -39.606% |
| Biovica International AB (publ) | -124.82 Million SEK | 70.301% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | 12.202% |
| Abliva AB (publ) | -95.5 Million SEK | 61.186% |
| Egetis Therapeutics AB (publ) | -326.9 Million SEK | 88.66% |
| 2cureX AB (publ) | -32.51 Million SEK | -14.001% |
| I-Tech AB | 20.2 Million SEK | 283.493% |
| Hansa Biopharma AB (publ) | -831.72 Million SEK | 95.543% |
| Cyxone AB (publ) | -22.98 Million SEK | -61.255% |
| ExpreS2ion Biotech Holding AB (publ) | -91.4 Million SEK | 59.441% |
| Biosergen AB | -27.03 Million SEK | -37.112% |
| Nanologica AB (publ) | -75.15 Million SEK | 50.675% |
| SynAct Pharma AB | -215.81 Million SEK | 82.822% |
| Annexin Pharmaceuticals AB (publ) | -44.05 Million SEK | 15.851% |
| BioInvent International AB (publ) | -330.3 Million SEK | 88.777% |
| Stayble Therapeutics AB (publ) | -23.73 Million SEK | -56.174% |
| Oncopeptides AB (publ) | -249.11 Million SEK | 85.119% |
| Pila Pharma AB (publ) | -9.93 Million SEK | -273.323% |
| Ascelia Pharma AB (publ) | -109.28 Million SEK | 66.08% |
| Diagonal Bio AB (publ) | -11.67 Million SEK | -217.443% |